FIELD: medicine.
SUBSTANCE: invention refers to a new derivative of anthrafurandione of formula I 
or its pharmaceutically acceptable salts possessing high antitumour effect and activity on tumours resistant to other drug preparations. Besides, the invention refers to antitumour pharmaceutical compositions containing the compound of formula I, a pharmacologically acceptable carrier and one or mode excipients specified in co-solvents, solubilisers, filling agents, emulsifiers, preserving agents, antioxidants, buffer compounds, substances for maintaining isotonicity.
EFFECT: effective use of anthrafurandione, as it possesses high storage stability as a lyophilisate, and as a solution, and also other improved characteristics, including solubility, efficacy and acceptability.
10 cl, 6 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ORAL ANTITUMOUR DRUGS AND METHOD FOR ONCOLOGICAL DISEASES TREATMENT | 2016 |
|
RU2639479C1 |
| PHARMACEUTICAL ANTITUMOR COMPOSITION BASED ON SALT OLIVOMICINE DERIVATIVE | 2017 |
|
RU2662087C1 |
| ANTI-TUMOR NAPHTHOINDOLE-3-CARBOXAMIDE DERIVATIVE | 2019 |
|
RU2712191C1 |
| ANTICANCER PHARMACEUTICAL COMPOSITIONS AND METHOD OF TREATING BREAST CANCER | 2015 |
|
RU2581022C1 |
| METHOD OF OBTAINING ANTHRA[2,3-b]FURAN-3-CARBOXYLIC ACID | 2014 |
|
RU2554937C1 |
| NEW HETEROARENANTHRACENE-2-CARBOXAMIDE DERIVATIVES INHIBITING TUMOUR GROWTH | 2016 |
|
RU2631100C1 |
| ANTITUMOR AGENT | 1998 |
|
RU2128042C1 |
| ANTITUMOR AGENT | 1996 |
|
RU2093158C1 |
| PHOSPHOLIPID COMPOSITION OF DOXORUBICIN FOR TREATING PATIENTS WITH BREAST CANCER | 2019 |
|
RU2714137C1 |
| CYTOTOXIC LINEAR HETEROCYCLIC DERIVATIVES OF ANTHRACENEDIONE HAVING IN SIDE CHAIN CYCLIC DIAMINES, ACTIVE TOWARDS TUMOUR CELLS WITH MULTIDRUG RESISTANCE | 2009 |
|
RU2412166C1 |
